#Sustainability #Hong Kong #ESG #WuXi Biologics

WuXi Biologics Achieves Sustainability Recognition

WuXi Biologics, traded under the stock code 2269.HK, has made headlines with its recent inclusion in the 2025 Hang Seng Corporate Sustainability Benchmark Index, marking a significant accomplishment as the only pharmaceutical company to earn this distinction. The announcement highlights the company’s unwavering commitment to sustainability practices within the realm of biologics.

The Hang Seng Corporate Sustainability Benchmark Index is designed to spotlight publicly listed companies that excel in environmental, social, and governance (ESG) performance. WuXi Biologics' recognition not only reflects its operational excellence but also underscores adherence to responsible practices that drive long-term improvement within the pharmaceutical industry.

Dr. Chris Chen, CEO of WuXi Biologics and chair of the company's ESG Committee, noted the importance of this recognition, stating, "Being included in the Hang Seng Indexes is a significant recognition of our continuous efforts in pursuing sustainability." He reinforced the company’s pledge to create lasting value for all stakeholders while positively impacting society and the environment.

WuXi Biologics has previously received accolades for its ESG performance, being named in both the HSI ESG Index and the Hang Seng ESG 50 Index. The recognition was awarded following a thorough assessment conducted by the Hong Kong Quality Assurance Agency (HKQAA). This evaluation serves as an independent endorsement of the company’s sustainable growth strategies.

At the core of WuXi Biologics’ operations is a commitment to integrating sustainability principles into its business model. The company focuses on enhancing technological innovation in green research and development, striving for optimal energy efficiency, maintaining transparent governance, and promoting employee welfare. Such efforts exemplify a holistic approach toward corporate responsibility and civic engagement.

In alignment with the United Nations Sustainable Development Goals (SDGs), WuXi Biologics actively collaborates with the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). Additionally, the company's commitment to sustainability has been recognized with notable achievements, including a recent endorsement from the Science Based Targets initiative (SBTi) concerning their greenhouse gas emissions-reduction strategy.

WuXi Biologics has been recognized by the global community for its sustainability initiatives, securing an MSCI AAA ESG rating, earning an EcoVadis Platinum Medal, and being listed in the Dow Jones Sustainability Indices. Other accolades include achieving a high rating from Sustainalytics and being acknowledged in the FTSE4Good Index Series.

The firm’s strong performance in the ESG sector is a testament to its underlying philosophy that views sustainability as a fundamental aspect of business growth. By developing green technology solutions for its partners worldwide, WuXi aims to promote responsible practices across the entire value chain, thereby reinforcing its position as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO).

As of June 30, 2025, WuXi Biologics supports a broad portfolio of 864 integrated client projects, including 24 in commercial manufacturing. This extensive scope showcases its capacity to deliver comprehensive service in biologics—from initial discovery phases through to commercialization.

WuXi Biologics’ recognition within the sustainability index charts a crucial step in the pharmaceutical sector's journey towards achieving significant environmental and social goals and encourages other companies to engage in similar practices.

For further information about WuXi Biologics and its commitment to sustainability, please visit www.wuxibiologics.com.